The Investor
11 Mar 2026, 18:44
DexCom announced new clinical data at the Advanced Technologies and Treatments for Diabetes (ATTD) 2026 conference showing that long-term use of its Dexcom G7 continuous glucose monitoring (CGM) system can improve A1C levels and support weight management in people with Type 2 diabetes who are not using insulin.
The company also presented evidence linking Dexcom CGM use with reduced hospitalizations and emergency visits related to diabetic ketoacidosis in patients with Type 1 diabetes.
Dexcom said the findings reinforce the potential for CGM technology to become a broader standard of care across diabetes populations, while the company also outlined upcoming product features and its future product roadmap during the conference.
Business Wire
The company also presented evidence linking Dexcom CGM use with reduced hospitalizations and emergency visits related to diabetic ketoacidosis in patients with Type 1 diabetes.
Dexcom said the findings reinforce the potential for CGM technology to become a broader standard of care across diabetes populations, while the company also outlined upcoming product features and its future product roadmap during the conference.
Business Wire
